Form 4: Keros Therapeutics Director, Carl L. Gordon, Acquires 10,000 Stock Options

Director Carl L. Gordon acquired 10,000 stock options in Keros Therapeutics, Inc. at an exercise price of $46.31 on May 30, 2024.

Summary

• Carl L. Gordon, a director of Keros Therapeutics, Inc., acquired 10,000 stock options on May 30, 2024.
• The exercise price for these options is $46.31.
• The options vest in equal quarterly installments over 12 months, fully vesting by the date of the Issuer's 2025 annual meeting of stockholders, contingent on continued service.
• Gordon is obligated to transfer any securities or economic benefits from these options to OrbiMed Advisors LLC and OrbiMed Capital GP VII LLC, which will then provide them to OrbiMed Private Investments VII, LP.

Sentiment

Score: 5

Explanation: The sentiment is neutral as it reflects a routine transaction of stock options being granted to a director. There is no indication of positive or negative implications for the company's performance.

Future Outlook

The options vest over the next 12 months, contingent on continued service, and will be fully vested by the date of the Issuer's 2025 annual meeting of stockholders.

Industry Context

This filing reflects standard insider transactions and is typical for directors receiving stock options as part of their compensation. It doesn't necessarily indicate a broader trend in the biotechnology industry but rather is specific to the individual's compensation package and company policies.

Comparison to Industry Standards

• Stock option grants to directors are a common practice in the biotech industry, often used to align the interests of directors with those of shareholders.
• The vesting schedule of 12 months is fairly standard.
• Companies like Amgen, Gilead Sciences, and Biogen also utilize stock options as part of their director compensation packages.

Related Party Transactions

• The Reporting Person is obligated to transfer any securities issued under any such stock options or other awards, or the economic benefit thereof, to OrbiMed Advisors LLC and OrbiMed Capital GP VII LLC, which will in turn ensure that such securities or economic benefits are provided to OrbiMed Private Investments VII, LP.

Stakeholder Impact

• The transaction itself has minimal direct impact on stakeholders.
• The vesting of the options could incentivize the director to act in the best interests of the shareholders over the vesting period.

Key Dates